bosentan anhydrous has been researched along with vasoactive intestinal peptide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaine, SP; O'Callaghan, D; O'Callaghan, DS | 1 |
| Hamidi, SA; Jiang, YP; Lin, RZ; Lyubsky, S; Said, SI; Szema, AM | 1 |
1 review(s) available for bosentan anhydrous and vasoactive intestinal peptide
| Article | Year |
|---|---|
Combination therapy and new types of agents for pulmonary arterial hypertension.
Topics: Adrenomedullin; Angiopoietin-1; Antihypertensive Agents; Benzamides; Bosentan; Drug Therapy, Combination; Eicosanoids; Epoprostenol; Genetic Therapy; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Piperazines; Platelet Aggregation Inhibitors; Prostaglandins; Protein Serine-Threonine Kinases; Purines; Pyrimidines; rho-Associated Kinases; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sildenafil Citrate; Sulfonamides; Sulfones; Vasoactive Intestinal Peptide; Vasodilator Agents | 2007 |
1 other study(ies) available for bosentan anhydrous and vasoactive intestinal peptide
| Article | Year |
|---|---|
VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.
Topics: Animals; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Monocrotaline; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Sulfonamides; Vasoactive Intestinal Peptide | 2011 |